留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

小肠移植受者长期疗效影响因素及其监控防治

王勉 陈冬利 吴国生 赵青川

王勉, 陈冬利, 吴国生, 等. 小肠移植受者长期疗效影响因素及其监控防治[J]. 器官移植, 2017, 8(4): 333-336. doi: 10.3969/j.issn.1674-7445.2017.04.018
引用本文: 王勉, 陈冬利, 吴国生, 等. 小肠移植受者长期疗效影响因素及其监控防治[J]. 器官移植, 2017, 8(4): 333-336. doi: 10.3969/j.issn.1674-7445.2017.04.018

小肠移植受者长期疗效影响因素及其监控防治

doi: 10.3969/j.issn.1674-7445.2017.04.018
基金项目: 

国家自然科学基金面上项目 81570588

详细信息
    通讯作者:

    赵青川, Email:zhaoqc@fmmu.edu.cn

  • 中图分类号: R617, R392.4

  • 摘要: 近些年来, 随着外科技术的发展和新型免疫抑制剂的出现, 小肠移植术成为治疗各种原因所致短肠综合征及不可逆性肠功能衰竭的首选手段之一。然而, 由于小肠本身为固有的高免疫原性、有菌的空腔器官等因素, 小肠移植术后长期疗效不甚理想。移植术后急、慢性排斥反应和感染等仍是影响患者长期存活的主要因素。随着对移植免疫反应的深入了解, 体液免疫因素在移植术后急、慢性排斥反应中的作用受到了人们的关注, 供体特异性抗体(DSA)与小肠移植后急、慢性排斥反应的发生发展密切相关。小肠移植术后长期疗效有赖于对排斥反应、感染等因素的有效监控防治及免疫耐受的形成。

     

  • [1] Lillehei RC, Idezuki Y, Feemster JA, et al. Transplantation of stomach, intestine, and pancreas: experimental and clinical observations[J]. Surgery, 1967, 62(4): 721-741. http://www.ncbi.nlm.nih.gov/pubmed/4862242
    [2] Grant D, Abu-Elmagd K, Mazariegos G, et al. Intestinal transplant registry report: global activity and trends[J]. Am J Transplant, 2015, 15(1): 210-219. DOI: 10.1111/ajt.12979.
    [3] 吴国生.临床活体小肠移植国内外研究进展[J/CD].中华结直肠疾病电子杂志, 2013, 2 (5): 221-223. DOI: 10.3877/cma.j.issn.2095-3224.2013. 05.03.

    Wu GS. Advances inliving-related small intestinal transplantation[J/CD]. Chin J Colorectal Dis(Electr Edit), 2013, 2 (5): 221-223. DOI: 10.3877/cma.j.issn. 2095-3224.2013.05.03.
    [4] 李元新.小肠移植发展现状、困惑与挑战[J].器官移植, 2016, 7(1): 8-13. DOI: 10.3969/j.issn.1674-7445.2016.01.002.

    Li YX. Development status, confusion and challenge of small bowel transplantation[J].Organ Transplant, 2016, 7(1): 8-13. DOI: 10.3969/j.issn.1674-7445.2016.01.002.
    [5] Wu GS, Cruz RJ Jr, Cai JC. Acute antibody-mediated rejection after intestinal transplantation[J]. World J Transplant, 2016, 6(4): 719-728. DOI: 10.5500/wjt.v6.i4.719.
    [6] Ruiz P, Carreno M, Weppler D, et al. Immediate antibody-mediated (hyperacute) rejection in small-bowel transplantation and relationship to cross-match status and donor-specific C4d-binding antibodies: case report[J]. Transplant Proc, 2010, 42(1): 95-99. DOI: 10.1016/j.transproceed.2009.12.025.
    [7] 姚丹华, 李幼生, 王剑, 等.小肠移植中应用单克隆抗体免疫诱导治疗的临床疗效观察[J].中华器官移植杂志, 2013, 34(8): 486-489. DOI: 10.3760/cma.j.issn.0254-1785.2013.08.011.

    Yao DH, Li YS, Wang J, et al. Clinical efficiency of monoclonal antibody induction therapy in intestinal transplantation[J]. Chin J Organ Transplant, 2013, 34(8): 486-489. DOI: 10.3760/cma.j.issn.0254-1785.2013.08.011.
    [8] Borker A, Choudhary N. Rituximab[J]. Indian Pediatr, 2011, 48(8): 627-632. doi: 10.1007/s13312-011-0098-6
    [9] Waddle ES, Alloway RR, Girnita A. Proteasome inhibitor treatment of antibody-mediated rejection[J]. Curr Opin Organ Transplant, 2011, 16(4): 434-438. DOI: 10.1097/MOT.0b013e328348c0e5.
    [10] de Serre NP, Canioni D, Lacaille F, et al. Evaluation of C4d deposition and circulating antibody in small bowel transplantation[J]. Am J Transplant, 2008, 8(6): 1290-1296. DOI: 10.1111/j.1600-6143.2008.02221.x.
    [11] Fujiwara S, Wada M, Kudo H, et al. Effectiveness of bortezomib in a patient with acute rejection associated with an elevation of donor-specific HLA antibodies after small bowel transplantation: case report[J]. Transplant Proc, 2016, 48(2): 525-527. DOI: 10.1016/j.transproceed.2015.09.073.
    [12] Doǧan SM, Kılınç S, Kebapçı E, et al. Mesenchymal stem cell therapy in patients with small bowel transplantation: single center experience[J]. World J Gastroenterol, 2014, 20(25): 8215-8220. DOI: 10.3748/wjg.v20.i25.8215.
    [13] Patil PB, Chougule PB, Kumar VK, et al. Recellularization of a cellular human small intestine using bone marrow stem cells[J]. Stem Cells Transl Med, 2013, 2(4): 307-315. DOI: 10.5966/sctm.2012-0108.
    [14] Florescu DF, Langnas AN, Sandkovksy U. Opportunistic viral infections in intestinal transplantation[J]. Expert Rev Anti Infect Ther, 2013, 11(4): 367-381. DOI: 10.1586/eri.13.25.
    [15] Avsar Y, Cicinnati VR, Kabar I, et al. Small bowel transplantation complicated by cytomegalovirus tissue invasive disease without viremia[J]. J Clin Virol, 2014, 60(2): 177-180. DOI: 10.1016/j.jcv.2014.03.005.
    [16] Florescu DF, Abu-Elmagd K, Mercer DF, et al. An international survey of cytomegalovirus prevention and treatment practices in intestinal transplantation[J]. Transplantation, 2014, 97(1): 78-82. DOI: 10.1097/TP.0b013e3182a6baa2.
    [17] Tzvetanov IG, Oberholzer J, Benedetti E. Current status of living donor small bowel transplantation[J]. Curr Opin Organ Transplant, 2010, 15(3): 346-348. DOI: 10.1097/MOT.0b013e3283398fa4.
    [18] Wu G, Cruz RJ. Live inclusion improves outcomes of intestinal retransplantation in adults[J].Transplantation, 2015, 99(6): 1265-1272. DOI: 10.1097/TP.0000000000000488.
    [19] Filler G, Huang SH. High prevalence of renal dysfunction also after small bowel transplantation[J]. Pediatr Transplant, 2013, 17(1): 8-11. DOI: 10.1111/petr.12025.
    [20] Ramos E, Hernández F, Andres A, et al. Post-transplant lymphoproliferative disorders and other malignancies after pediatric intestinal transplantation: incidence, clinical features and outcome[J]. Pediatr Transplant, 2013, 17(5): 472-478. DOI: 10.1111/petr.12103.
  • 加载中
计量
  • 文章访问数:  180
  • HTML全文浏览量:  85
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-05-10
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2017-07-15

目录

    /

    返回文章
    返回